Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
Decisions regarding treatment for advanced or metastatic gastroesophageal cancers require that clinicians be familiar with new and existing chemotherapy agents and targeted therapies as well as the current evidence regarding the survival rates and toxicities associated with various treatment approaches.
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. In addition, clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. In addition, clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.

Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.

Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.

This information was originally presented at the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™ held on March 26, 2017.

Surgical resection is the primary method of obtaining a potential cure for patients with gastric adenocarcinoma. However, chemotherapy or chemoradiotherapy offer significant improvement in survival over surgery alone.

This information was originally presented at the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.

Pages

Subscribe to RSS - Gastric/Esophageal Cancer